Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures
M. A. Pizzorno, O. Terrier, C. Nicolas de Lamballerie, T. Julien, B. Padey, A. Traversier, M. Roche, M.-E. Hamelin, C. Rheaume, S. Croze, V. Escuret, J. Poissy, B. Lina, C. Legras-Lachuer, J. Textoris, , M. Rosa-Calatrava
This paper identifies 35 FDA-approved drugs with antiviral potential against influenza using transcriptomic signatures, validates 31 in vitro, and highlights diltiazem as a promising candidate for Phase II clinical trials.
bioRxiv · Aug 27, 2018Microbiology